QUOTE AND NEWS
Benzinga  May 23  Comment 
Repros Therapeutics (NASDAQ: RPRX) today announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered product, in the treatment of uterine fibroids. The FDA recommended that a Phase 2b study should...
StreetInsider.com  May 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Repros+Therapeutics%2C+Inc.+%28RPRX%29+Posts+Q1+Loss+of+41cShare/8326165.html for the full story.
TheStreet.com  May 9  Comment 
THE WOODLANDS, Tex. (TheStreet) -- Investors who have read through Repros Therapeutics' regulatory filings know about the unresolved and worrisome patent conflict involving the company's testosterone-boosting pill Androxal. Less known but more...
Stock Blog Hub  Apr 21  Comment 
Repros Therapeutics Inc. (RPRX) recently announced that two additional patents covering its candidate, Androxal, have been issued. Both patents (8,372,887 and 8,377,991) related to metabolic consequences of low testosterone and the favorable...
StreetInsider.com  Apr 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Repros+%28RPRX%29+Receives+Two+More+Patents+Covering+Androxal+Indications/8245142.html for the full story.
TheStreet.com  Apr 5  Comment 
5. Repros Reproach Markets were closed last Friday in honor of Good Friday. Luckily for us, Repros Therapeutics CEO Joe Podolski generously provided more than enough dumbness last Thursday to tide us through the long holiday weekend. ...
StreetInsider.com  Mar 28  Comment 
Repros Therapeutics Inc. (Nasdaq: RPRX) 77.3% HIGHER; reported top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism. Results for the Intent-to-Treat population met both co-primary endpoints...
TheStreet.com  Mar 28  Comment 
THE WOODLANDS, Texas (TheStreet) -- Yes, Repros Therapeutics CEO Joe Podolski really did get on a conference call Thursday morning to say that his experimental testosterone drug Androxal helped gay Cubans have more sex. The gay Cubans...
Benzinga  Mar 28  Comment 
Repros Therapeutics (NASDAQ: RPRX) shares advanced 66.37% to $15.19 after the company announced top-line results for the first pivotal study of Androxal. LiveDeal (NASDAQ: LIVE) surged 34.69% to $3.65. LiveDeal shares have dropped 38.27% over...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki